The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Use a concentration of 1 µg/ml. Predicted molecular weight: 15 kDa. for 2 hours. This antibody has been tested in Western blot against the recombinant peptide used as an immunogen. We have no data on detection of endogenous protein.
1/2000 - 1/5000.
RelevanceCfPV2 is a novel canine papillomavirus. Papillomaviruses are highly host- and tissue-tropic, and are rarely transmitted between species. Papillomaviruses replicate exclusively in the basal layer of the body surface tissues. All known papillomavirus types infect a particular body surface, typically the skin or mucosal epithelium of the genitals, anus, mouth, or airways. CfPV2 induces papillomas on footpads and interdigital regions which, if infection is persistent, can progress to highly metastatic squamous cell carcinoma. CfPV2 does not induce oral papillomas in immunocompetent animals and antibodies generated against COPV and CfPV2 are type-specific.
E6 is a 151 amino-acid peptide that incorporates a type 1 motif. E6 is of particular interest because it appears to have multiple roles in the cell and to interact with many other proteins. Its major role, however, is to mediate the degradation of p53, a major tumor suppressor protein, reducing the cell's ability to respond to DNA damage. Overall, the E6 protein serves to impede normal protein activity in such a way as to allow a cell to grow and multiply at the increased rate characteristic of cancer.
CPV2 gp1 antibody
Early protein E6 antibody
References for Anti-CfPV2 E6 antibody (ab93861)
has not yet been referenced specifically in any publications.
Publishing research using ab93861? Please let us know so that we can cite the reference in this datasheet.
Concentration of lot no. is
Concentration not available for this lot.
Find concentration of your lot:
Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"